209 related articles for article (PubMed ID: 17261761)
1. TGF-beta signaling in breast cancer.
Buck MB; Knabbe C
Ann N Y Acad Sci; 2006 Nov; 1089():119-26. PubMed ID: 17261761
[TBL] [Abstract][Full Text] [Related]
2. Can transforming growth factor-beta1 and retinoids modify the activity of estradiol and antiestrogens in MCF-7 breast cancer cells?
Czeczuga-Semeniuk E; Anchim T; Dziecioł J; Dabrowska M; Wołczyński S
Acta Biochim Pol; 2004; 51(3):733-45. PubMed ID: 15448735
[TBL] [Abstract][Full Text] [Related]
3. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer.
Brandt S; Kopp A; Grage B; Knabbe C
Anticancer Res; 2003; 23(1A):223-9. PubMed ID: 12680217
[TBL] [Abstract][Full Text] [Related]
4. A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer.
Beisner J; Buck MB; Fritz P; Dippon J; Schwab M; Brauch H; Zugmaier G; Pfizenmaier K; Knabbe C
Cancer Res; 2006 Aug; 66(15):7554-61. PubMed ID: 16885354
[TBL] [Abstract][Full Text] [Related]
5. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma.
Ghellal A; Li C; Hayes M; Byrne G; Bundred N; Kumar S
Anticancer Res; 2000; 20(6B):4413-8. PubMed ID: 11205281
[TBL] [Abstract][Full Text] [Related]
7. The effect of antiestrogens on TGF-beta-mediated chemotaxis of human breast cancer cells.
Tong GM; Rajah TT; Zang XP; Pento JT
Anticancer Res; 2002; 22(1A):103-6. PubMed ID: 12017270
[TBL] [Abstract][Full Text] [Related]
8. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.
Yoo YA; Kang MH; Kim JS; Oh SC
Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246
[TBL] [Abstract][Full Text] [Related]
9. Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas.
Zhang F; Lundin M; Ristimäki A; Heikkilä P; Lundin J; Isola J; Joensuu H; Laiho M
Cancer Res; 2003 Aug; 63(16):5005-10. PubMed ID: 12941827
[TBL] [Abstract][Full Text] [Related]
10. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM
Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339
[TBL] [Abstract][Full Text] [Related]
12. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway.
Katsuno Y; Hanyu A; Kanda H; Ishikawa Y; Akiyama F; Iwase T; Ogata E; Ehata S; Miyazono K; Imamura T
Oncogene; 2008 Oct; 27(49):6322-33. PubMed ID: 18663362
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.
Joffroy CM; Buck MB; Stope MB; Popp SL; Pfizenmaier K; Knabbe C
Cancer Res; 2010 Feb; 70(4):1314-22. PubMed ID: 20145137
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
17. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
19. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta 1 could be a missing link in the interplay between ER and HER-2 in breast cancer.
Todorović-Raković N
Med Hypotheses; 2005; 65(3):546-51. PubMed ID: 15913903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
